PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|May 1, 2002
- Pharmaceutical Technology-05-02-2002
- Volume 26
- Issue 5
Analytical Data Management and Archiving: 21 CFR Part 11 Compliance and Beyond
Author(s)Kevin Smith
Pharma laboratories are having to manage and archive more analytical data than ever before. With effective implementation of IT systems, companies can successfully prepare their electronic files for future retieval and use.
Advertisement
Articles in this issue
over 24 years ago
Harmonizing Standards and Specificationsover 24 years ago
Polymers in Transdermal Drug Delivery Systemsover 24 years ago
Expanding the Use of Child-Resistant Packagingover 24 years ago
Outsourcing Outlookover 24 years ago
E-Procurement — Reverse Auctions and the Supplier's PerspectiveAdvertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Lessons For AI Governance in Quality Systems
5